ARQT – Cup & Handle Breakout Setup toward 23 and 34NASDAQ:ARQT is forming a large cup & handle base spanning over a year, with neckline resistance at 17.75 (blue line). A confirmed breakout above 17.80 would complete the bullish pattern, projecting upside targets first toward the prior major resistance at 23.00 and ultimately toward 34.00 based on
Arcutis Biotherapeutics, Inc.
No trades
No trades
Peers for comparison
0.23 USD
−16.14 M USD
376.07 M USD
110.17 M
Last report date
Report period
EPS
Revenue
Earnings release details
Q3 revenue rose 45% YoY to $143.9M, prompting higher FY 2026 guidance of $535M-$545M. Demand remained strong, while commercial and pipeline investment is aimed at a 2027 sales inflection.
Company info
Sector
Industry
CEO
Todd Franklin Watanabe
Website
Headquarters
Westlake Village
Founded
2016
IPO date
Jan 31, 2020
ISIN
US03969K1088
CUSIP
03969K108
FIGI
BBG00QN8K4M4
Identifiers
ISIN US03969K1088
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
ARQT - long - momentum and catalyst playArcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targe
January Gainers (ARQT, account up 1%)3rd gainer in January is ARQT . Holding period is 15 days (12/20/22-1/4/23). Account up 1%.
This month till today, my account is up 2.5%, average holding period is 12 days.
My trading method is mostly short term and is independent of market swings.
Will keep updating on my trades.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral
An aggregate view of professional's ratings.
Neutral
Neutral
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, ARQT trades at 27.53 USD.
For broader market analysis, dive into the technicals on the Arcutis Biotherapeutics, Inc. stock price chart and read the latest ARQT news:
– ARQT: 2027 catalysts build on ZORYVE momentum and a $2.3B-$3.5B peak-sales opportunity
– Weekly Recap: Q3 revenue growth and ZORYVE Phase 3 dermatitis trial
– Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
For broader market analysis, dive into the technicals on the Arcutis Biotherapeutics, Inc. stock price chart and read the latest ARQT news:
– ARQT: 2027 catalysts build on ZORYVE momentum and a $2.3B-$3.5B peak-sales opportunity
– Weekly Recap: Q3 revenue growth and ZORYVE Phase 3 dermatitis trial
– Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Markets don't sleep, here's what's going on with ARQT at the moment:
– ARQT: 2027 catalysts build on ZORYVE momentum and a $2.3B-$3.5B peak-sales opportunity
– Weekly Recap: Q3 revenue growth and ZORYVE Phase 3 dermatitis trial
– Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See more updates in real-time with our News Flow.
– ARQT: 2027 catalysts build on ZORYVE momentum and a $2.3B-$3.5B peak-sales opportunity
– Weekly Recap: Q3 revenue growth and ZORYVE Phase 3 dermatitis trial
– Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
See more updates in real-time with our News Flow.
Arcutis Biotherapeutics, Inc. is scheduled to release its next earnings report on Mar 2, 2027.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
ARQT stock is 5.43% volatile and has beta coefficient of 0.72.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ARQT are typically less volatile than smaller companies
Track every detail on Arcutis Biotherapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Arcutis Biotherapeutics, Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ARQT are typically less volatile than smaller companies
Track every detail on Arcutis Biotherapeutics, Inc. stock chart and check out the list of the most volatile stocks — is Arcutis Biotherapeutics, Inc. there?
To understand the ARQT stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +3.63%
– 1 week — −13.70%
– 1 month — +6.93%
ARQT all-time low was 1.76 USD (Dec 1, 2023), and its highest price is 40.88 USD (Mar 20, 2020). Find more dynamics in the Stock Heatmap and on the Arcutis Biotherapeutics, Inc. stock chart.
– 1 day — +3.63%
– 1 week — −13.70%
– 1 month — +6.93%
ARQT all-time low was 1.76 USD (Dec 1, 2023), and its highest price is 40.88 USD (Mar 20, 2020). Find more dynamics in the Stock Heatmap and on the Arcutis Biotherapeutics, Inc. stock chart.
Arcutis Biotherapeutics, Inc. market capitalization is 3.59 B, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Arcutis Biotherapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Arcutis Biotherapeutics, Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Arcutis Biotherapeutics, Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Arcutis Biotherapeutics, Inc. stacks up against other companies
The safest way to buy Arcutis Biotherapeutics, Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade ARQT directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade ARQT directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 13, 2026, the company has 354 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Arcutis Biotherapeutics, Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Arcutis Biotherapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our ARQT technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — buy
– 1-month — buy
Combine fundamental and technical analysis for better results.
First, study Arcutis Biotherapeutics, Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our ARQT technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — buy
– 1-month — buy
Combine fundamental and technical analysis for better results.
Arcutis Biotherapeutics, Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Arcutis Biotherapeutics, Inc. stocks trade under the symbol ARQT.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
ARQT earnings for the last quarter are 0.06 USD per share, whereas the estimation was 0.18 USD, resulting in a −66.67% surprise. The estimated earnings for the next quarter are 0.20 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Arcutis Biotherapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Arcutis Biotherapeutics, Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Arcutis Biotherapeutics, Inc. revenue for the last quarter amounts to 143.92 M USD despite the estimated figure of 142.59 M USD. In the next quarter revenue is expected to reach 163.07 M USD.
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Arcutis Biotherapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
How to read this data:
– Compare actual vs estimates: Revenue beats or misses can move the stock
– Watch market reaction: Price response shows how investors interpret results
– Look at growth: Compare with previous quarters and year-over-year data
– Track trends: One quarter matters less than consistent performance
Follow other essential metrics in Arcutis Biotherapeutics, Inc. financials:
– Earnings (EPS): Profitability per share
– Margins (gross, operating): Efficiency and cost control
– Free cash flow: Cash available after expenses
Yes, you can track Arcutis Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
ARQT net income for the last quarter is 8.80 M USD, while the quarter before that showed 15.01 M USD of net income which accounts for −41.36% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Arcutis Biotherapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Arcutis Biotherapeutics, Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
No, Arcutis Biotherapeutics, Inc. does not currently pay dividends to its shareholders.
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
Instead of distributing profits as cash payments, the company may choose to reinvest earnings back into the business — for example, in growth, innovation, acquisitions, or debt reduction.
What to consider instead:
– Earnings growth: Is the company increasing profitability over time?
– Revenue expansion: Is the business scaling its operations?
– Free cash flow: Does it generate enough cash to potentially support future dividends?
– Share buybacks: Some companies return capital through repurchasing shares instead of dividends
ARQT reached its all-time high of 40.88 USD on Mar 20, 2020. Its all-time low was 1.76 USD and was reached on Dec 1, 2023.
Explore the Arcutis Biotherapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Arcutis Biotherapeutics, Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Arcutis Biotherapeutics, Inc. EBITDA is 38.11 M USD, with an EBITDA margin of −1.82%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Arcutis Biotherapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Arcutis Biotherapeutics, Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 34.00 USD and 48.00 USD for ARQT, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance







